US55083R1041

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell…

13 hours ago

June 23, 2025 17:00 ET | Source: Lyell Immunopharma, Inc SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) --…

6 months ago